Woodmont Investment Counsel’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$605K Sell
10,507
-205
-2% -$11.8K 0.03% 179
2026
Q1
$650K Hold
10,712
0.04% 168
2025
Q4
$578K Sell
10,712
-699
-6% -$33.6K 0.04% 172
2025
Q3
$515K Sell
11,411
-547
-5% -$25.5K 0.03% 176
2025
Q2
$554K Sell
11,958
-1,138
-9% -$55.9K 0.04% 193
2025
Q1
$799K Buy
13,096
+90
+0.7% +$5.25K 0.06% 158
2024
Q4
$736K Buy
13,006
+391
+3% +$21.8K 0.05% 157
2024
Q3
$653K Sell
12,615
-3,074
-20% -$144K 0.05% 165
2024
Q2
$652K Sell
15,689
-1,230
-7% -$55K 0.05% 161
2024
Q1
$918K Sell
16,919
-1,686
-9% -$85.9K 0.08% 143
2023
Q4
$955K Sell
18,605
-5,445
-23% -$286K 0.09% 132
2023
Q3
$1.4M Sell
24,050
-2,660
-10% -$163K 0.15% 107
2023
Q2
$1.71M Sell
26,710
-270
-1% -$18.1K 0.18% 103
2023
Q1
$1.87M Sell
26,980
-25
-0.1% -$1.76K 0.2% 96
2022
Q4
$1.94M Sell
27,005
-100
-0.4% -$7.54K 0.22% 94
2022
Q3
$1.93M Buy
27,105
+148
+0.5% +$10.7K 0.24% 89
2022
Q2
$2.08M Buy
26,957
+310
+1% +$23.6K 0.26% 89
2022
Q1
$1.95M Sell
26,647
-877
-3% -$58.9K 0.22% 91
2021
Q4
$1.72M Buy
27,524
+645
+2% +$37.8K 0.22% 94
2021
Q3
$1.59M Sell
26,879
-469
-2% -$30.9K 0.23% 88
2021
Q2
$1.83M Buy
27,348
+1,943
+8% +$127K 0.29% 77
2021
Q1
$1.6M Buy
25,405
+1,354
+6% +$84.2K 0.27% 80
2020
Q4
$1.49M Sell
24,051
-75
-0.3% -$4.61K 0.28% 75
2020
Q3
$1.46M Buy
24,126
+875
+4% +$52.7K 0.31% 73
2020
Q2
$1.37M Buy
23,251
+2,525
+12% +$151K 0.33% 72
2020
Q1
$1.16M Sell
20,726
-321
-2% -$19.6K 0.32% 75
2019
Q4
$1.35M Buy
21,047
+600
+3% +$34.4K 0.31% 78
2019
Q3
$1.04M Buy
20,447
+1,170
+6% +$55K 0.25% 90
2019
Q2
$874K Sell
19,277
-300
-2% -$14K 0.22% 98
2019
Q1
$934K Sell
19,577
-1,731
-8% -$86.2K 0.24% 94
2018
Q4
$1.11M Buy
21,308
+1,675
+9% +$90K 0.31% 77
2018
Q3
$1.22M Sell
19,633
-1,834
-9% -$109K 0.33% 74
2018
Q2
$1.19M Sell
21,467
-2,161
-9% -$117K 0.33% 79
2018
Q1
$1.49M Sell
23,628
-3,450
-13% -$222K 0.41% 66
2017
Q4
$1.66M Sell
27,078
-325
-1% -$20.3K 0.43% 67
2017
Q3
$1.75M Sell
27,403
-950
-3% -$55.5K 0.48% 63
2017
Q2
$1.58M Sell
28,353
-190
-0.7% -$10.3K 0.45% 74
2017
Q1
$1.67M Hold
28,543
0.48% 69
2016
Q4
$1.67M Buy
28,543
+700
+3% +$38.3K 0.48% 69
2016
Q3
$1.5M Buy
27,843
+21,200
+319% +$1.36M 0.43% 71
2016
Q2
$489K Buy
6,643
+520
+8% +$36.7K 0.15% 137
2016
Q1
$391K Sell
6,123
-266
-4% -$16.8K 0.12% 138
2015
Q4
$439K Sell
6,389
-404
-6% -$26.7K 0.13% 140
2015
Q3
$402K Hold
6,793
0.12% 143
2015
Q2
$452K Sell
6,793
-434
-6% -$28.6K 0.13% 138
2015
Q1
$466K Sell
7,227
-400
-5% -$25K 0.14% 131
2014
Q4
$450K Sell
7,627
-250
-3% -$14.1K 0.14% 132
2014
Q3
$403K Hold
7,877
0.12% 159
2014
Q2
$382K Hold
7,877
0.11% 164
2014
Q1
$409K Buy
7,877
+200
+3% +$10.6K 0.12% 159
2013
Q4
$408K Sell
7,677
-1,465
-16% -$74.6K 0.12% 152
2013
Q3
$423K Buy
9,142
+350
+4% +$15.4K 0.15% 131
2013
Q2
$393K Buy
+8,792
New +$382K 0.13% 152

Other funds holding BMY

Woodmont Investment Counsel's BMY Position: Q2 2026 in Review

Woodmont Investment Counsel reduced its Bristol-Myers Squibb (BMY) stake by 1.9% in Q2 2026, selling an estimated $11.8K and leaving 10,507 shares worth $605K. The position accounts for 0.03% of the portfolio, ranked #179.

Woodmont Investment Counsel first reported a position in BMY in Q2 2013 and has held it in 53 quarters since. The position peaked at $2.08M in Q2 2022. 1,603 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Woodmont Investment Counsel held 10,507 shares of Bristol-Myers Squibb worth $605K as of Q2 2026.
  • Woodmont Investment Counsel sold 205 Bristol-Myers Squibb shares in Q2 2026, an estimated $11.8K.
  • Bristol-Myers Squibb made up 0.03% of Woodmont Investment Counsel's portfolio in Q2 2026, its #179 holding.
  • Woodmont Investment Counsel first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 53 quarters since.
  • Woodmont Investment Counsel's Bristol-Myers Squibb position peaked at $2.08M in Q2 2022.
  • 1,603 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Woodmont Investment Counsel's 13F filing for Q2 2026, filed 27 Jul 2026.